Commvault Systems Inc vs Cassava Sciences Inc — how do they compare? Commvault Systems Inc trades at $151.43 (market cap $6.23B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Commvault Systems Inc is far larger — about 158.1× Cassava Sciences Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Cassava Sciences Inc for 37 Days on average.
| CVLT | FLNA | |
|---|---|---|
Market Cap | $6.23B | $39.40M |
Volume | 720,354 | 759,018 |
Sector | Technology | Health |
52-Week High | $176.52 | $4.64 |
52-Week Low | $75.18 | $0.68 |
Typical Hold Time | 17 Days | 37 Days |
Enterprise Value | $6.22B | -$43.28M |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.28, down 3.03% on the day, but maintains a bullish technical outlook with strong institutional support. The company shows robust revenue growth, with 2026 projections reaching $1.2 billion, though net income margins are expected to compress. Recent positive developments include AWS competency achievements and new board appointments, while analyst consensus remains strongly bullish with a $156.55 price target.
CVLT presents a compelling growth story with consistent earnings beats and expanding enterprise partnerships, but faces valuation concerns with elevated P/E and P/B ratios. The stock's upside potential is supported by strong institutional buying and positive technical momentum, though investors should monitor margin pressures and competitive threats in the data resilience space.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →